Annovis Bio (NYSE: ANVS) has promoted Cheng Fang, Ph.D., to chief scientific officer, the company announced. Fang, who joined Annovis in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across the company's Alzheimer's disease and Parkinson's disease programs.
The promotion comes at a critical juncture for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer's disease study and a subsequent New Drug Application submission. Fang has played a key role in advancing the company's clinical development efforts and will lead its scientific strategy through upcoming clinical and regulatory milestones, according to the company.
Fang's responsibilities will include translational science, clinical development, biomarker strategy and regulatory interactions. His deep expertise in neurodegenerative disease research is expected to be instrumental as Annovis prepares for potential regulatory submissions. The company is developing buntanetap, an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action.
Annovis Bio is a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. By addressing the underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit annovisbio.com.
The announcement underscores Annovis's commitment to advancing its pipeline as it approaches key milestones. The full press release is available at https://ibn.fm/c9jdt. Investors can find the latest news and updates relating to ANVS in the company's newsroom at https://ibn.fm/ANVS.
